Study of HER-2/neu status in adenocarcinoma of stomach and gastroesophageal junction

Nigar Fathima; Michelle de Padua; Swarnalata Gowrishankar; Iravathy Goud

doi:10.18203/2320-6012.ijrms20205311

Authors

Nigar Fathima Department of Histopathology, Apollo Hospitals, Hyderabad, Telangana, India
Michelle de Padua Department of Histopathology, Apollo Hospitals, Hyderabad, Telangana, India
Swarnalata Gowrishankar Department of Histopathology, Apollo Hospitals, Hyderabad, Telangana, India
Iravathy Goud Department of Molecular Biology and Cytogenetics, Apollo Hospitals, Hyderabad, Telangana, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20205311

Keywords:

Gastric carcinoma, Gastroesophageal junction, Gene amplification, HER-2/neu, Trastuzumab

Abstract

Background: To study the expression of Human epidermal growth factor receptor 2 (HER-2/neu) in adenocarcinoma of stomach and gastroesophageal junction and to study and describe the association of HER-2/neu expression with various clinicopathological parameters in Indian population.

Methods: Immunohistochemical testing was done on 91 cases diagnosed as adenocarcinoma of gastric and gastroesophageal junction by histological examination to determine HER2 status. HER2 amplification was confirmed by fluorescence in situ hybridization (FISH) on cases that had equivocal (immunohistochemistry-IHC score 2+) HER2 expression. The association between HER-2 positivity and clinicopathological parameters was assessed by Chi-square test.

Results: The HER-2 IHC results are as follows: score 3+ (positive): 8.79%; score 2+ (equivocal): 10.99%; score 0 and 1+ (negative): 80.22%. Of the 10 cases of equivocal IHC results, 2 cases (20%) showed amplification of HER-2 gene demonstrated by dual probe FISH analysis. The overall prevalence of HER-2 positivity detected using immunohistochemistry and FISH was 10.99% (10/91 cases). HER-2 positivity correlated with the tumor grade (well and moderately differentiated tumor, p=0.013) and intestinal type (p=0.025) but not with age, gender, pathological stage and lymph node metastasis.

Conclusions: HER-2 positivity in our study was 10.99%. HER-2 positivity significantly correlated with intestinal type of adenocarcinoma and the grade of the tumor. Two cases with strong HER-2 staining but in less than 10% of the tumor showed gene amplification by FISH.

Metrics

Metrics Loading ...

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-97.

Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127-37.

Halon A, Donizy P, Biecek P, Rudno-Rudzinska J, Kielan W, Matkowski R. HER-2 expression in immunohistochemistry has no prognostic significance in gastric cancer patients. Scientific World Journal. 2012;2012:1-6.

Tewari M, Kumar A, Mishra R, Kumar M, Shukla HS. HER2 expression in gastric and gastroesophageal cancer: report from a tertiary care hospital in north India. Indian J Surg. 2015;77(2):447-51.

Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand. 1965;64:31-49.

Ruschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25(5):637-50.

Wolff A, Hammond M, Hicks D, Dowsett M, McShane L, Allison K, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997-4013.

Xie S, Xu C, Shen J, Jiang Z, Shen J, Wang L. HER 2/neu protein expression in gastric cancer is associated with poor survival. Mol Med Rep. 2009;2(6):943-6.

Motojima K, Furui J, Kohara N, Izawa K, Kanematsu T, Shiku H. erbB-2 expression in well-differentiated adenocarcinoma of the stomach predicts shorter survival after curative resection. Surgery. 1994;115(3):349-54.

Kim K, Koh Y, Chang H, Kim T, Yook J, Kim B, et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol. 2011;18(10):2833-40.

Ramon JM, Serra L, Cerdo C, Oromi J. Dietary factors and gastric cancer risk. A case-control study in Spain. Cancer. 1993;71(5):1731-5.

Laboissiere RS, Buzelin MA, Balabram D, De Brot M, Nunes CB, Rocha RM, et al. Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections. BMC Gastroenterol. 2015;15:157.

Patil PS, Mehta SA, Mohandas KM. Over-expression of HER2 in Indian patients with gastric cancer. Indian J of Gastroenterol. 2013;32(5):350.

Sunitha N, Champaka G, Kumar RV, Lakshmaiah KC. HER2/neu Expression in Gastric and Esophagogastric Junction Adenocarcinoma. Int J Sci Study. 2017;5(3):61-6.

Aditi R, Aarathi R, Pradeep R, Hemalatha L, Akshatha C, Amar K. HER2 Expression in Gastric Adenocarcinoma—a Study in a Tertiary Care Centre in South India. Indian J Surg Oncol. 2016;7(1):18-24.

Sekaran A, Kandagaddala R, Darisetty S, Lakhtakia S, Ayyagari S, Rao G, et al. HER2 expression in gastric cancer in Indian population- an immunohistochemistry and fluorescence in situ hybridization study. Indian J Gastroenterol. 2012;31(3):106-10.

Halder S, Mallick D, Mondal P, Roy DS, Halder A, Chakrabarti S. Detection and significance of human epidermal growth factor receptor 2 expression in gastric adenocarcinoma. Indian J Med Paediatr Oncol. 2017;38(2):153.

Gupta P, Rao S, Bhalla S. Human epidermal growth factor receptor 2 expression in gastric carcinoma and its association with histopathological parameters in Indian population. Indian J Cancer. 2016;53:505-11.

Rajagopal I, Niveditha SR, Sahadev R, Nagappa PK, Rajendra SG. HER 2 expression in gastric and gastro-esophageal junction ( GEJ ) adenocarcinomas. J Clin Diagn Res. 2015;9(3):6-10.

Ghosh P, Chakrabarti I, Bhowmick S, Gangopadhyay M, Sinha MG, Bhattacharya S. Overexpression of Her2/Neu in Gastric Carcinoma: association with histological type, tumor grade and H. Pylori infection. Annals of Pathology and Lab Medicine. 2016;3(3):183-8.

Figueroa-Barojas P, Zarate-Osorno A, Quinonez-Urrego EE, Sobrino-Cossío S, Hernandez-Guerrero A. Clinical significance of HER2/neu overexpression in advanced gastric cancer. ImmunoGastroenterol. 2012;1(2):136-42.

Cidon EU, Centeno RG, Lagarto EG, Peral JI. HER-2 evaluation in a specific gastric cancer population with the highest rate of mortality in Spain. J Oncol. 2011;2011:1-6.

Shan L, Ying J, Lu N. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. Diagn Pathol. 2013;8(1):76.

Barros-Silva JD, Leitao D, Afonso L, Vieira J, Dinis-Ribeiro M, Fragoso M, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer. 2009;100:487-93.